Market Trends of South America Bladder Cancer Therapeutics and Diagnostics Industry
Cystoscopy Segment Expects to Register a Significant Growth Over the Forecast Period
Cystoscopy is a procedure used to observe the interiors of the bladder and urethra using a telescope. A cystoscope is a specialized endoscope that is inserted through the urethra into the bladder to allow direct visual inspection of the urothelium. Cystoscopy is cost-effective. The segment is driven by rising in the adoption of cystoscopy, the rising prevalence of bladder cancer, and product launches by the key market players.
According to an article published in BMC, in February 2021, it has been observed that fluorescent cystoscopy using 5-aminolevulinic acid (ALA) or its hexyl ester, hexaminolevulinate improves tumor detection rate and recurrence-free survival (RFS) compared to white-light cystoscopy alone, in bladder cancer treatment. This is expected to increase the adoption of cystoscopy in the diagnosis of bladder cancer which in turn is anticipated to augment the segment's growth over the forecast period.
Therefore, owing to the aforementioned factors, such as the high adoption of cystoscopy, the studied market is expected to grow over the forecast period.
Brazil is Expected to Have the Significant Market Share Over the Forecast Period
Brazil is expected to witness a significant share in the bladder cancer therapeutics and diagnostics market over the forecast period. The factors propelling the market growth are the increasing burden of various types of bladder cancer and rising research studies.
According to an article published in the Journal of Epidemiology and Global Health, in September 2022, it has been observed that bladder cancer is the seventh most prevalent cancer in men and the sixteenth most prevalent cancer in women, in Brazil. Thus, the high burden of bladder cancer among the Brazillian population raises the demand for effective therapeutics and diagnostics devices which in turn is anticipated to fuel the market growth over the forecast period.
Additionally, the growing company activities in developing various diagnostic tests and products to effectively diagnose bladder cancer among the population is expected to fuel the market growth over the forecast period. For instance, in January 2023, Hoffmann-La Roche is conducting a Phase III clinical study to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with muscle-invasive bladder cancer who are ctDNA positive and are at high risk for recurrence following cystectomy, in Brazil. Also, in April 2021, Solve Biotechnology researchers, a Brazillian start-up company, are developing a rapid test to diagnose bladder cancer to reduce the number of invasive tests to which patients are submitted from the discovery of cancer to the end of treatment.
Therefore, owing to the above-mentioned factors such as the high burden of bladder cancer and increasing company activities, the studied market is expected to grow in Brazil over the forecast period.
